Investment Thesis
Protara is a pre-commercial biotech company with essentially zero revenue (178K) and $21.3M quarterly cash burn, indicating either failed clinical programs or absence of marketed products. With only $14.7M in cash and a burn rate suggesting less than one year runway, the company faces imminent capital needs or insolvency risk absent major operational changes or external funding.
Strengths
- Strong balance sheet with $181.2M stockholders equity and minimal debt
- No long-term debt obligations providing financial flexibility
- High liquidity ratios (15.69x current/quick) indicating near-term solvency
Risks
- Critical cash runway of less than one year at current burn rate ($21.3M quarterly operating cash burn against $14.7M cash)
- Non-existent revenue base with $178K representing 101.2% YoY decline
- Massive operating losses of $19.6M against minimal revenue indicating failed or incomplete clinical development
Key Metrics to Watch
- Cash burn rate and months of cash runway remaining
- Clinical trial progress and regulatory milestones for pipeline programs
- Capital raising activities or partnerships to extend runway
Financial Metrics
Revenue
178.0K
Net Income
-17.8M
EPS (Diluted)
$-0.31
Free Cash Flow
-21.4M
Total Assets
191.9M
Cash
14.7M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-11,027.5%
Net Margin
-9,989.9%
ROE
-9.8%
ROA
-9.3%
FCF Margin
-12,043.3%
Balance Sheet & Liquidity
Current Ratio
15.69x
Quick Ratio
15.69x
Debt/Equity
0.00x
Debt/Assets
5.6%
Interest Coverage
N/A
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-16T10:25:33.307007 |
Data as of: 2026-03-31 |
Powered by Claude AI